Hormone replacement therapy and endometrial, ovarian and colorectal cancer

被引：57

作者：

Gambacciani, M ^{[1
]}

Monteleone, P ^{[1
]}

Sacco, A ^{[1
]}

Genazzani, AR ^{[1
]}

机构：

[1] Dept Reprod Med & Child Dev, Div Obstet & Gynecol, Pisa, Italy

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2003年 / 17卷 / 01期

关键词：

hormone replacement therapy; menopause; endometrial cancer; ovarian cancer; colorectal cancer;

D O I：

10.1016/S1521-690X(02)00086-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sex-steroid-related tumours in women are represented by breast cancer and endometrial cancer, but a possible relationship may exist between sex steroids and both ovarian and colon cancer. Unopposed oestrogen therapy is known to increase the risk of endometrial cancer and is appropriate only for hysterectomized women. In women with an intact uterus, an appropriate combination of oestrogen and progestin does not appear to increase-and may even decrease-the risk of endometrial cancer. Current users of HRT seem to benefit from a reduced risk for colon cancer. As for epithelial ovarian cancer, the present data are very conflicting. The association between replacement hormones and this malignancy seems to be stronger for unopposed oestrogen than for oestrogen-progestin treatment. Data available at the moment do not allow discriminating for dose, routes of administration, bioavailability and tissue effects of different compounds so that it is inappropriate to consider all forms of HRT jointly. The future of HRT in post-menopausal women lies in the individualization of the therapy based upon personal risk factors and characteristics.

引用

页码：139 / 147

页数：9

共 52 条

[1]

Bhavnani BR, 1998, P SOC EXP BIOL MED, V217, P6

[2] Adverse endometrial effects during long cycle hormone replacement therapy [J].

Bjarnason, K ;

Cerin, Å ;

Lindgren, R ;

Weber, T .

MATURITAS, 1999, 32 (03) :161-170

[3]

BRINTON LA, 1993, OBSTET GYNECOL, V81, P265

[4]

Campbell-Thompson M, 2001, CANCER RES, V61, P632

[5] Estrogen replacement in surgical stage I and II endometrial cancer survivors [J].

Chapman, JA ;

DiSaia, PJ ;

Osann, K ;

Roth, PD ;

Gillotte, DL ;

Berman, ML .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (05) :1195-1200

[6]

CREASMAN WT, 1986, OBSTET GYNECOL, V67, P326

[7] The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].

Cummings, SR ;

Eckert, S ;

Krueger, KA ;

Grady, D ;

Powles, TJ ;

Cauley, JA ;

Norton, L ;

Nickelsen, T ;

Bjarnason, NH ;

Morrow, M ;

Lippman, ME ;

Black, D ;

Glusman, JE ;

Costa, A ;

Jordan, VC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197

[8] Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens [J].

Cushing, KL ;

Weiss, NS ;

Voigt, LF ;

McKnight, B ;

Beresford, SAA .

OBSTETRICS AND GYNECOLOGY, 1998, 91 (01) :35-39

[9]

Duffield-Lillico AJ, 2002, CANCER EPIDEM BIOMAR, V11, P630

[10]

Fernandez E, 1998, CANCER EPIDEM BIOMAR, V7, P329

← 1 2 3 4 5 6 →